<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376752</url>
  </required_header>
  <id_info>
    <org_study_id>FEDEGYN 02 / 0410-CHIPOR</org_study_id>
    <secondary_id>2010-023035-42</secondary_id>
    <nct_id>NCT01376752</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment</brief_title>
  <acronym>CHIPOR</acronym>
  <official_title>A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial
      ovarian cancer is able to improve the median OS by 12 months. In that hypothesis, with alpha
      risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years
      follow-up, the number of patients to include is 404. Taking into account a 10% failure, an
      overall number of 444 patients is required.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient received before the surgery a second line chemotherapy, platinum-based regimen
      with either carboplatine-paclitaxel, or carboplatine-caelyx. At the end of the six courses IV
      chemotherapy, if the disease is still responding and if a complete cytoreductive surgery
      seems possible, the patient is included after signed informed consent and will be operated 5
      to 8 weeks after the last second-line chemotherapy cycle.

      So, during the surgery the patient will be randomized if the complete cytoreductive surgery
      is really done and will then receive:

        -  either treatment A = maximal cytoreductive surgery without HIPEC

        -  or treatment B = maximal cytoreductive surgery with HIPEC

      The HIPEC will be done at the end of the surgery. At the end of cytoreductive surgery, tumor
      residual disease must be null or very limited (Sugarbaker completeness cytoreduction: CC0 (no
      residual)-CC1 (residual &lt; 0.25cm).

      Two methods will be used for the HIPEC: Open or closed abdomen, depends on the site practice.
      Each site will use the same method during the study for all included patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>from randomization to death (up to 4 years)</time_frame>
    <description>There is a follow-up period of 4 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>from randomization to relapse (up to 4 years)</time_frame>
    <description>There is a follow-up period of 4 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>maximal cytoreductive surgery</intervention_name>
    <description>maximal cytoreductive surgery with or without HIPEC For HIPEC : the cisplatin will be used at 75mg/m2</description>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age ≥ 18 yrs,

          -  Performance Status OMS &lt; 2,

          -  Initially treated for Epithelial Ovarian Carcinoma

          -  Patient with only peritoneal relapse occurred at least 6 month from the initial
             treatment, resectable without distant metastasis (with the exception of communicating
             pleura effusion, sensitive to platine-based second line chemotherapy and resectable
             lymph-nodes in the groin or retro peritoneal)

          -  Platinum based second-line chemotherapy before surgery with either
             carboplatine-paclitaxel, or carboplatine-caelyx

          -  Complete cytoreductive surgery

          -  The surgery has to be planned 5 to 8 weeks from the last 2nd of chemotherapy

          -  No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT et ALAT ≤ 3 time the
             Upper Normal Limit,

          -  No Renal insufficiency (serum creatinine &lt; 1,5 time the normal limit, creatinine
             clearance &gt;60 ml/min). calculated with MDRD method

          -  Hematology function : PNN ≥1,5x109/L, platelets ≥ 100x109/L,

          -  No contraindication to general anaesthesia for heavy surgery

          -  Patients having read, signed and dated Informed consent before any study procedure

          -  childbearing patients have to take appropriate contraceptive methods during the
             treatment and until 6 months after the treatment

        Exclusion Criteria:

          -  Patient age &lt;18 years

          -  Previous cancer in the last 5 years (except cutaneous baso-cellular epithelioma or
             uterine peripheral epithelioma)

          -  Hypersensitivity to Platinum compound

          -  Distant metastasis

          -  Use of anti-angiogenic treatment,

          -  Patient with other concurrent severe life threatening disease

          -  The need to perform more than two segmental digestive resections during the CRS +/-
             HIPEC surgery

          -  Any progressive disease during the IV systemic second-line chemotherapy
             (platine-based)

          -  Incomplete cytoreductive surgery with macroscopical residual disease (Sugarbaker&gt;CC1)

          -  Early relapse: less than 6 mois after the end of the first treatment.

          -  Ovarian tumor other than Epithelioma Ovarian Cancer

          -  Uncontrolled infection,

          -  Patients with any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule,

          -  Clinically significant cardiovascular disease contraindicating the hyper hydratation,
             which is necessary for HIPEC,

          -  Patient already treated with HIPEC for the ovarian cancer

          -  Individual deprived of liberty or placed under the authority of a tutor.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc CLASSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre rené Gauducheau, NANTES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trevor Stanbury</last_name>
    <phone>+33 1 44 23 55 67</phone>
    <email>t-stanbury@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriel LIBERALE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie SANGUIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard LORIMIER, Doctor</last_name>
      <email>g.lorimier@angers.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Romuald WERNERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitaleir Universitaire Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa KALBACHER, Dr</last_name>
      <email>ekalbacher@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elsa KALBACHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GUYON, Doctor</last_name>
      <email>guyon@bergonie.org</email>
    </contact>
    <investigator>
      <last_name>Frédéric GUYON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen Cedex 3</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc GUILLOIT, Doctor</last_name>
      <email>jm.guilloit@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc GUILLOIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand Cedex 1</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian POMEL, Pr</last_name>
      <email>Christophe.POMEL@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Christian POMEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc ROUSSELET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien PETITPERRIN</last_name>
      <email>FPetitperrin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien PETITPERRIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristina COSTAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LEBLANC, Dr</last_name>
      <email>e-leblanc@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LEBLANC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvaine DURAND-FONTANIER, Doctor</last_name>
      <email>sylvainedurand-fontanier@voila.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvaine DURAND-FONTANIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MEEUS, Doctor</last_name>
      <email>MEEUS@lyon.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre MEEUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles HOUVENAEGHEL, Pr</last_name>
      <email>houvenaeghelg@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles HOUVENAEGHEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aubert AGOSTINI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François QUENET</last_name>
      <email>francois.quenet@montpellier.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>François QUENET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nice - Hopital L'Archet 2</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc BEREDER, Dr</last_name>
      <email>ber224@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc BEREDER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc POCARD</last_name>
      <email>marc.pocard@lrb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc POCARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valeria LOI, Dr</last_name>
      <email>valeria.loi@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Valeria LOI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice LECURU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascale MARIANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BARANGER</last_name>
      <email>bernard.baranger@curie.net</email>
    </contact>
    <investigator>
      <last_name>Bernard BARANGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GLEHEN, Professor</last_name>
      <email>olivier.glehen@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier GLEHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cédric NADEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Godinot</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David KERE, Dr</last_name>
      <email>david.kere@reims.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>David KERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Saint Etienne- Hopital Nord</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine ABBOUD, Dr</last_name>
      <email>abboud_go@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Karine ABBOUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ico-Centre Rene Gauducheau</name>
      <address>
        <city>Saint-herblain Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc CLASSE, Professor</last_name>
      <email>jm-classe@nantes.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc CLASSE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile BRIGAND</last_name>
      <email>cecile.brigand@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile BRIGAND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaël FERRON, Doctor</last_name>
      <email>ferron.gwenael@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaël FERRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL, Pr</last_name>
      <email>f.marchal@nancy.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric MARCHAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien GOUY, Doctor</last_name>
      <email>sebastien.gouy@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien GOUY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan José TORRENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

